Physician profile
Abid Rasool
NPI 1750462594
$5,955.24
in general payments reported to CMS, 2019-2025
58 companies · $876 in 2025
The $876 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $560 · 2021: $1,224 · 2022: $887 · 2023: $764 · 2024: $655 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.58 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,020.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ibsa Pharma INC. | $470.26 | 2021-2025 | Tirosint, Licart, Tirosint |
| Abbvie INC. | $388.21 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $356.46 | 2019-2023 | |
| Astellas Pharma US INC | $351.67 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $315.67 | 2019-2023 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.68 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $266.19 | 2019-2024 | Zepbound, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $221.99 | 2019-2025 | Trelegy Ellipta |
| Insulet Corporation | $185.72 | 2024-2025 | Omnipod |
| Esperion Therapeutics, INC. | $171.99 | 2020-2023 | Nexletol |
| Pfizer INC. | $163.10 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $136.65 | 2021-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.58 | 2019-2024 | Trulance, Xifaxan |
| Centinel Spine, LLC | $125.00 | 2019 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abid Rasool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.